RxDoctor Payments DataLook up a doctor →

David Wilkins, PA

Medical · Muskegon, MINPI 1740230200

Payments from drug & device makers

$41,058in general payments, 2019–2025

Across 1,269 payments — averaging $32.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$24K
  • AbbVie$3K
  • Supernus Pharmaceuticals, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$983
  • Novo Nordisk$973
  • Lilly USA, LLC$937
  • plus $10K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)122$23,640
AbbVie(2 entities)233$3,088
Supernus Pharmaceuticals, Inc.78$1,069
Teva Pharmaceuticals USA, Inc.80$983
Novo Nordisk65$973
Lilly USA, LLC74$937
Boehringer Ingelheim58$918
Pfizer48$775
AstraZeneca29$764
GSK66$726
Alkermes, Inc.35$671
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)35$655
Otsuka America Pharmaceutical, Inc.32$483
Takeda Pharmaceuticals U.S.A., Inc.36$461
Lundbeck LLC23$338
Johnson & Johnson23$330
Axsome Therapeutics, Inc.13$322
Astellas Pharma US Inc10$259
Vanda Pharmaceuticals Inc.12$256
Biohaven Pharmaceutical Holding Company Ltd.11$247
Bayer14$232
Neurocrine Biosciences, Inc.9$179
Biohaven Pharmaceuticals, Inc.10$179
Corium, LLC13$177
Sunovion Pharmaceuticals Inc.11$167
Indivior Inc.10$166
Novartis9$156
Mylan Specialty L.p.9$150
Xeris Pharmaceuticals, Inc.6$129
E.r. Squibb & Sons, L.L.C.7$128
Alnylam Pharmaceuticals Inc.7$126
Paratek Pharmaceuticals, Inc.7$114
Collegium Pharmaceutical, Inc.7$107
Ardelyx, Inc.5$104
Dexcom, Inc.4$91
Abiomed1$74
Philips North America LLC4$71
Ironwood Pharmaceuticals, Inc3$59
Sumitomo Pharma America, Inc.4$57
Antares Pharma, Inc.4$56
Exact Sciences3$49
Merck4$48
Nestle Healthcare Nutrition Inc.2$42
Phathom Pharmaceuticals, Inc.5$40
Tris Pharma Inc2$38
Sanofi-aventis U.S. LLC2$34
UCB, Inc.2$34
Avadel CNS Pharmaceuticals, LLC2$33
Alfasigma USA, Inc.2$30
Viatris Specialty LLC1$28
Kowa Pharmaceuticals America, Inc.2$24
Eisai Inc.1$24
Pulmonx Corporation1$24
Organon1$19
Medtronic1$18
Idorsia Pharmaceuticals US Inc1$18
Otsuka Pharmaceutical Development & Commercialization, Inc.1$18
Corcept Therapeutics1$16
Insulet Corporation1$15
Avanir Pharmaceuticals, Inc.1$14

How this compares

$41,058 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$56,229
Medicare patients
99
Services billed
1,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical in Muskegon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →